<DOC>
	<DOCNO>NCT01292603</DOCNO>
	<brief_summary>This randomize , parallel-group , multi-center study compare pharmacokinetics safety subcutaneous administration MabThera ( rituximab ) versus intravenous MabThera combination chemotherapy previously untreated patient chronic lymphocytic leukemia ( CLL ) . The study consist 2 part . In part 1 , patient previously receive 4 cycle intravenous MabThera receive Cycle 5 intravenous MabThera Cycle 6 subcutaneous MabThera . In part 2 , patient randomize receive either 6 cycle intravenous MabThera , 1 cycle intravenous MabThera 5 cycle subcutaneous MabThera . Additionally , patient receive chemotherapy ( fludarabine cyclophosphamide ) Days 1-3 Days 1-5 every cycle . The anticipated time study drug 24 week .</brief_summary>
	<brief_title>A Study Compare Subcutaneous Versus Intravenous MabThera ( Rituximab ) Combination With Chemotherapy Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Patients treatmentrequiring chronic lymphocytic leukemia ( CLL ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Life expectancy &gt; 6 month Transformation aggressive Bcell malignancy History malignancy unless patient treat curative intent remission 5 year prior enrolment HIV Hepatitis B positive unless clearly due vaccination Inadequate liver renal function Any coexist medical psychological condition would preclude participation require study procedure Additional exclusion criterion Part 1 : Any previous treatment CLL except 4 cycle rituximab IV combination FC chemotherapy firstline treatment CLL Additional exclusion criterion Part 2 : Any previous treatment CLL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>